secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001628280-23-016254
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Therapeutics Q1 net loss $30.5M, cash $316M; FHD-286 mUM data expected Q2 2023
--------------------------------------------------------------------------------

- Net loss of $30.5M for Q1 2023, compared to $26.9M loss in Q1 2022; no product revenue.
- Cash and equivalents $316M as of March 31, 2023, providing runway into second half of 2025.
- Phase 1 dose escalation of FHD-286 in metastatic uveal melanoma continues; top-line data expected Q2 2023.
- FDA clinical hold on FHD-286 in AML/MDS; regulatory update expected Q2 2023.
- Collaboration revenue $5.3M, up from $3.9M; Loxo@Lilly collaboration progressing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828023016254/0001628280-23-016254-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828023016254/fhtx-20230508.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-016254

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer